
Jeplus.in
Purchase All Medicines.Get 10% Offer

Express Pharma
Fitusiran is indicated for routine prophylaxis to prevent or reduce bleeding episodes in adults and adolescents aged 12 years and older, with or without factor VIII or IX inhibitors The post CDSCO approves Sanofi’s Qfitlia for haemophilia A and B in India appeared first on Express Pharma.

Express Pharma
The partnership will cover technology transfer, clinical manufacturing and commercial production of VeGen Bio’s VL-2511 in India The post Nucelion Therapeutics, VeGen Bio collaborate on CAR-T cell therapy manufacturing appeared first on Express Pharma.

Pharma Tech
AbbVie is just one of several pharmaceutical companies to pen sponsorship deals in sport, blurring the commercial line between the two industries.

Express Pharma
On the sidelines of the Bengaluru Pharma Summit, Dr. Villoo Morawala Patell, Founder & Chairperson of Avesthagen Limited and The Avestagenome Project® International, speaks with Neha Aathavale, Correspondent, Express Pharma […] The post Exclusive Interview with Dr. Villoo Morawala Patell, Founder & Chairperson of Avesthagen Limited and The Avestagenome Project® International appeared first on Express Pharma.

Pharma Tech
Consolidating complicated supply chains with trusted providers reduces governance, sharpens cost and emissions insight, and creates a more resilient, coordinated network.
Sponsored content

Purchase All Medicines.Get 10% Offer
News
PharmaShots
Oct 21, 2026, 12:25 PM
Shots: NewAmsterdam and Menarini Report the EC Approval for Ubeslo and Evlarco for Primary Hypercholesterolemia                 Company: NewAmsterdam and Menarini                 Product: Ubeslo and Evlarco                Active Ingredient: Obicetrapib and Obicetrapib + Ezetimibe FDC                Disease: Primary Hypercholesterolemia                Date: Sep 21, 2026                  Shots:  Editor’s Take: Beyond the Headlines  The EC approvals of Ubeslo and Evlarco give NewAmsterdam and Menarini… The post EMA Marketing Authorization of New Drugs in September 2026 appeared first on PharmaShots.
PharmaShots
Oct 21, 2026, 11:30 AM
Shots: Ref: Rapport |  Image: Rapport  | Press Release PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com The post Rapport Therapeutics Reports Topline P-II Trial Results on RAP-219 in Bipolar Mania appeared first on PharmaShots.
PharmaShots
Oct 21, 2026, 11:28 AM
Shots: Takeda has reported data from the randomized P-IV (VERDICT) treat-to-target trial, conducted by Alimentiv in collaboration with Takeda, evaluating IV Entyvio (vedolizumab) in adults (N=672) with moderate to severe ulcerative colitis (UC) randomized to 3 increasingly stringent corticosteroid-free (CSF) targets: symptomatic remission (Group 1), symptomatic + endoscopic remission (Group 2), or disease clearance (symptomatic… The post Takeda Reports P-IV (VERDICT) Treat-to-Target Trial Data of Entyvio (Vedolizumab) for Ulcerative Colitis at UEGW 2026 appeared first on PharmaShots.
PharmaShots
Oct 21, 2026, 11:21 AM
Shots: Ref: GlobeNewswire  |  Image: TISSIUM  | Press Release PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com The post TISSIUM Receives CE Mark for Eclipsium to Enable Atraumatic Mesh Fixation in Ventral Hernia Repair appeared first on PharmaShots.
PharmaShots
Oct 21, 2026, 11:21 AM
Shots: Lumen Bioscience has reported results from the P-II (RePreve) trial evaluating oral LMN-201 vs PBO, given during & after SoC antibiotics, in pts (N=45; Part A: 22, Part B: 23) with C. difficile infection (CDI); Part B was a 1:1 randomized, double-blind, PBO-controlled cohort In Part B, global cure was achieved in 83.3% (10/12)… The post Lumen Bioscience Reports P-II (RePreve) Trial Results of LMN-201 for C. difficile Infection appeared first on PharmaShots.
PharmaShots
Oct 21, 2026, 11:21 AM
Shots: Shionogi & F2G have reported data from the global, adjudicator-blinded P-III (OASIS) trial evaluating oral olorofim (150mg, BID on Day 1, then 90mg, BID; up to 84 days) vs IV AmBisome (3mg/kg, QD) followed by SoC in adults (N=225; 2:1) with invasive aspergillosis for whom mould-active azole therapy was inappropriate or ineffective; data will… The post Shionogi and F2G Report P-III (OASIS) Trial Data of Olorofim for Invasive Aspergillosis appeared first on PharmaShots.
News
Google News
Oct 22, 2026, 2:40 AM
FDA patient, consumer reps often tied to pharma-funded groups  Medical Xpress
Google News
Oct 22, 2026, 2:30 AM
Black market weight-loss drug sellers are moving fast. South Africa’s regulators are struggling to keep up  Bhekisisa
Google News
Oct 22, 2026, 2:04 AM
IIT-Madras opens finishing school for biotech grads  The New Indian Express
Google News
Oct 22, 2026, 1:33 AM
[Inside Chodong] K-Biotech Has No Patient CapitalÂ Â ě•„ě‹śě•„ę˛˝ě ś
Google News
Oct 22, 2026, 1:02 AM
Gold Coast hosts Australia's Biggest Week in Biotech as AusBiotech turns 40Â Â BiotechDispatch
Google News
Oct 22, 2026, 1:02 AM
BioNTech opens mRNA plant, putting Melbourne's north on the biotech map  BiotechDispatch
Google News
Oct 22, 2026, 12:41 AM
LAL Control Standard Endotoxin Market To 2035: Growth Driven by Pharma QC and Electronics Cleanroom Demand - News and Statistics  IndexBox
Google News
Oct 22, 2026, 12:27 AM
Kolon Biotech to Participate in BIX 2026, Showcase Cell and Gene Therapy CDMO CapabilitiesÂ Â ě•„ě‹śě•„ę˛˝ě ś
Google News
Oct 22, 2026, 12:24 AM
Bio 'Avengers' Formed... Kolmar Biotech Launches 'Bio-One Infinity'  파이낸셜뉴스
Sponsored placement

Purchase All Medicines.Get 10% Offer